Epidemiological characteristics and progress in diagnosis and treatment of esophageal cancer with human immunodeficiency virus/acquired immune deficiency syndrome_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

LI Dan ,  YAO Xiaojun

Department of Thoracic Surgery, Public Health Clinical Center of Chengdu, Chengdu, 610000, P. R. China;

Corresponding?author：

YAO Xiaojun, Email: flyingyao@163.com

Keywords：

Esophageal cancer; human immunodeficiency virus; acquired immune deficiency syndrome; epidemiological characteristics; diagnosis and treatment; review

DOI：

10.7507/1007-4848.202301025

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Human immunodeficiency virus (HIV) infection mainly attacks the human immune system, causing a variety of opportunistic infections and tumors, among which neoplastic diseases are serious and life-threatening. In recent years, with the popularization of highly effective anti-retroviral virus, the disease spectrum of HIV infected people has changed greatly, the incidence of non-acquired immune deficiency syndrome (AIDS) related tumors has increased significantly, and the diagnosis rate of esophageal cancer patients with HIV/AIDS has also increased. However, there is no consensus on how to standardize the diagnosis and treatment of esophageal cancer patients with HIV/AIDS. This article reviews the epidemiological characteristics, diagnosis and treatment of esophageal cancer patients with HIV/AIDS.

Citation： LI Dan, YAO Xiaojun. Epidemiological characteristics and progress in diagnosis and treatment of esophageal cancer with human immunodeficiency virus/acquired immune deficiency syndrome. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(11): 1684-1689. doi: 10.7507/1007-4848.202301025 Copy

1.	Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS, 2017, 12(1): 6-11.
2.	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
3.	劉宇英, 魏君麗, 江柔, 等. 食管癌的流行病學及篩查研究進展. 中華疾病控制雜志, 2022, 26(7): 839-844.Liu YY, Wei JL, Jiang R, et al. Research progress on the epidemiology and screening of esophageal cancer. Chin J Dis Control Prev, 2022, 26(7): 839-844.
4.	Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 2018, 6(5): e555-e567.
5.	Kayamba V, Bateman AC, Asombang AW, et al. HIV infection and domestic smoke exposure, but not human papillomavirus, are risk factors for esophageal squamous cell carcinoma in Zambia: A case-control study. Cancer Med, 2015, 4(4): 588-595.
6.	Tanaka LF, Latorre MDRDO, Gutierrez EB, et al. Cancer survival in people with AIDS: A population-based study from S?o Paulo, Brazil. Int J Cancer, 2018, 142(3): 524-533.
7.	雷海科, 李小升, 李杰平, 等. 艾滋病合并惡性腫瘤患者臨床特點及預后影響因素. 腫瘤防治研究, 2022, 49(5): 412-417.Lei HK, Li XS, Li JP, et al. Clinical characteristics and prognostic influence factors of patients with AIDS-related malignant tumor. Cancer Res Prev Treat, 2022, 49(5): 412-417.
8.	雷海科, 李小升, 趙玉蘭, 等. 2011―2018年重慶多中心惡性腫瘤出院患者生存分析. 中國腫瘤, 2020, 29(3): 192-198.Lei HK, Li XS, Zhao YL, et al. Survival of discharged malignant tumor patients from multi-centers in Chongqing from 2011 to 2018. China Cancer, 2020, 29(3): 192-198.
9.	胡俊華, 胡艷秋, 許紅霞, 等. 佳木斯市艾滋病抗病毒治療患者生存率及影響因素分析. 中國現代醫生, 2021, 59(19): 10-13.Hu JH, Hu YQ, Xu HX, et al. Analysis of survival rate and influencing factors of AIDS patients treated with antiviral therapy in Jiamusi City. China Mod Doct, 2021, 59(19): 10-13.
10.	鄭武, 趙丁源, 張薇, 等. 湖北省2008—2018年艾滋病抗病毒治療患者生存及影響因素分析. 中國熱帶醫學, 2020, 20(5): 417-422.Zheng W, Zhao DY, Zhang W, et al. Survival time and influence factors of HAART in Hubei, 2008- 2018. China Trop Med, 2020, 20(5): 417-422.
11.	中華醫學會感染病學分會艾滋病丙型肝炎學組, 中國疾病預防控制中心. 中國艾滋病診療指南 (2021年版). 協和醫學雜志, 2022, 13(2): 203-226.Acquired Immunodeficiency Syndrome and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection /acquired immunodeficiency syndrome (2021 edition). Med J Peking Union Med Coll Hosp, 2022, 13(2): 203-226.
12.	Mremi A, Mswima J, Mlay MG, et al. Cancer spectrum in HIV-infected patients: A zonal hospital experience in Tanzania. Cancer Treat Res Commun, 2020, 25: 100213.
13.	Gheorghi?? V, Conea IF, Radu AMC, et al. Epidemiological trends and therapeutic challenges of malignancies in adult HIV-1-infected patients receiving combination antiretroviral therapy in a tertiary hospital from Romania: An observational retrospective study. J Infect Public Health, 2019, 12(2): 182-189.
14.	黃曦悅, 石明巧, 茍瑜, 等. 64例HIV/AIDS患者合并腫瘤臨床特征分析. 四川醫學, 2018, 39(7): 743-747.Huang XY, Shi MQ, Gou Y, et al. Analysis of the clinical features of 64 cases of HIV/AIDS patients with tumor. Sichuan Med J, 2018, 39(7): 743-747.
15.	張珂, 熊英, 吳立春, 等. 腫瘤患者中HIV感染狀況的初步調查分析. 腫瘤預防與治療, 2011, 24(2): 83-85.Zhang K, Xiong Y, Wu LC, et al. Investigation of HIV infection status in cancer patients. Cancer Res Prev Treat, 2011, 24(2): 83-85.
16.	陳瓊, 徐慧芳, 劉曙正, 等. 2010—2016年河南省食管癌發病與死亡情況趨勢分析. 中華腫瘤雜志, 2022, 44(1): 86-92.Chen Q, Xu HF, Liu SZ, et al. Changing trend of incidence and mortality of esophageal cancer during 2010-2016 in Henan Province, China. Chin J Oncol, 2022, 44(1): 86-92.
17.	Alongi F, Giaj-Levra N, Sciascia S, et al. Radiotherapy in patients with HIV: Current issues and review of the literature. Lancet Oncol, 2017, 18(7): e379-e393.
18.	Thrift AP, Kramer JR, Hartman CM, et al. Risk and predictors of esophageal and stomach cancers in HIV-infected veterans: A matched cohort study. J Acquir Immune Defic Syndr, 2019, 81(3): e65-e72.
19.	Holleczek B, Sch?ttker B, Brenner H. Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: Results from the prospective population-based ESTHER cohort study. Int J Cancer, 2020, 146(10): 2773-2783.
20.	Fialho AB, Braga-Neto MB, Guerra EJ, et al. Low prevalence of H. pylori infection in HIV-positive patients in the northeast of Brazil. BMC Gastroenterol, 2011, 11: 13.
21.	Hestvik E, Tylleskar T, Ndeezi G, et al. Prevalence of Helicobacter pylori in HIV-infected, HAART-na?ve Ugandan children: A hospital-based survey. J Int AIDS Soc, 2011, 14: 34.
22.	Vohlonen IJ, Hakama M, H?rk?nen M, et al. Oesophageal cancer incidence in 20-year follow-up in a population-based sample of 12 000 middle-age men with or without Helicobacter pylori infection in Finland. Gut, 2018, 67(6): 1201-1202.
23.	Wilcox CM. Esophageal disease in the acquired immunodeficiency syndrome: Etiology, diagnosis, and management. Am J Med, 1992, 92(4): 412-421.
24.	Guaitoli G, Baldessari C, Maur M, et al. Treating cancer with immunotherapy in HIV-positive patients: A challenging reality. Crit Rev Oncol Hematol, 2020, 145: 102836.
25.	張永喜, 桂希恩, 鐘亞華, 等. 艾滋病病毒感染人群中惡性腫瘤的常見類型及其生存分析. 腫瘤研究與臨床, 2010, 22(11): 764-766.Zhang YX, Gui XE, Zhong YH, et al. Spectrum and survival of cancer in cohort of HIV-infected population. Cancer Res Clin, 2010, 22(11): 764-766.
26.	Torres HA, Mulanovich V. Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis, 2014, 59(1): 106-114.
27.	霍小東, 于振濤. 多學科團隊在食管癌診斷與治療中的作用. 中國腫瘤臨床, 2016, 43(12): 502-506.Huo XD, Yu ZT. The role of a multidisciplinary team in diagnosing and treating esophageal cancer. Chin J Clin Oncol, 2016, 43(12): 502-506.
28.	Mwachiro M, Mitchell E, Topazian HM, et al. Esophagectomy in patients with human immunodeficiency virus and acquired immune deficiency syndrome: A viable option. Semin Thorac Cardiovasc Surg, 2018, 30(1): 116-121.
29.	Davakis S, Syllaios A, Meropouli A, et al. Minimally invasive oesophagectomy for cancer in patients with HIV/AIDS: Considerations and future directions. Ann R Coll Surg Engl, 2020, 102(9): e1-e3.
30.	中國性病艾滋病防治協會學術委員會外科學組, 中華醫學會熱帶病與寄生蟲學分會外科學組, 國家傳染病醫學中心(北京). 中國人類免疫缺陷病毒感染者圍手術期抗病毒治療專家共識 (第二版). 中華實驗和臨床感染病雜志(電子版), 2021, 15(5): 289-294.Surgical Group of Chinese Association of STD and AIDS Prevention and Control, Surgical Group of Tropical Disease and Parasitology Branch of Chinese Medical Association, National Medical Center for Infectious Diseases (Beijing). Expert consensus on perioperative antiviral therapy for human immunodeficiency virus infected population in China (Second edition). Chin J Exp Clin Infect Dis (Electron Ed), 2021, 15(5): 289-294.
31.	Guild GN, Moore TJ, Barnes W, et al. CD4 count is associated with postoperative infection in patients with orthopaedic trauma who are HIV positive. Clin Orthop Relat Res, 2012, 470(5): 1507-1512.
32.	Li J, Li H, Zeng H, et al. A study protocol of population-based cancer screening cohort study on esophageal, stomach and liver cancer in rural China. Chin J Cancer Res, 2020, 32(4): 540-546.
33.	王付亮. 食管癌新輔助化療. 河北醫科大學, 2018.Wang FL. Neo-adjuvant chemotherapy for esophageal cancer. Hebei Medical University, 2018.
34.	Yano T, Kasai H, Horimatsu T, et al. A multicenter phaseⅡstudy of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Oncotarget, 2017, 8(13): 22135-22144.
35.	Kelly RJ. Immunotherapy for esophageal and gastric cancer. Am Soc Clin Oncol Educ Book, 2017, 37: 292-300.
36.	路遙, 孟祥瑞, 許孟麗, 等. PD-1/PD-L1抑制劑在食管癌臨床研究進展. 食管疾病, 2020, 2(3): 222-227.Lu Y, Meng XR, Xu ML, et al. Clinical research progress of PD-1/PD-L1 inhibitors in esophageal cancer. J Esophag Dis, 2020, 2(3): 222-227.
37.	Phakathi BP, Basson G, Karusseit VOL, et al. The effect of HIV infection on the surgical, chemo- and radiotherapy management of breast cancer. A prospective cohort study. Int J Surg, 2016, 34: 109-115.
38.	Issa RA, Podbielski FJ, Fontaine JP, et al. Esophagectomy in a patient with AIDS. Dis Esophagus, 2004, 17(3): 270-272.
39.	夏咸軍, 劉保池. 艾滋病與惡性腫瘤. 上海醫藥, 2013, 34(16): 11-14.Xia XJ, Liu BC. AIDS and cancer. Shanghai Med Pharm J, 2013, 34(16): 11-14.
40.	國家衛生健康委員會. 食管癌診療規范(2018年版). 中華消化病與影像雜志(電子版), 2019, 9(4): 158-192.National Health Commission. Esophageal cancer diagnostic and treatment guidelines (2018 edition). Chin J Digest Med Imageol (Electron Ed), 2019, 9(4): 158-192.
41.	Formenti SC, Chak L, Gill P, et al. Increased radiosensitivity of normal tissue fibroblasts in patients with acquired immunodeficiency syndrome (AIDS) and with Kaposi's sarcoma. Int J Radiat Biol, 1995, 68(4): 411-412.
42.	Wijsman JA, Dekaban GA, Rieder MJ. Differential toxicity of reactive metabolites of clindamycin and sulfonamides in HIV-infected cells: Influence of HIV infection on clindamycin toxicity in vitro. J Clin Pharmacol, 2005, 45(3): 346-351.
43.	Pajonk F, Himmelsbach J, Riess K, et al. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res, 2002, 62(18): 5230-5235.
44.	Wolchok JD, Chan TA. Cancer: Antitumour immunity gets a boost. Nature, 2014, 515(7528): 496-498.
45.	Vanpouille-Box C, Pilones KA, Wennerberg E, et al. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine, 2015, 33(51): 7415-7422.
46.	丁祥, 于淑慧, 龍清, 等. 人類免疫缺陷病毒陽性惡性腫瘤患者放射治療的急性放射性反應觀察. 中華放射醫學與防護雜志, 2015, 35(9): 687-689.Ding X, Yu SH, Long Q, et al. Acute adverse effects of radiotherapy on HIV-positive patients with malignancy. Chin J Radiol Med Prot, 2015, 35(9): 687-689.
47.	Quéro L, Palich R, Valantin MA, et al. The role of radiotherapy in treating Kaposi's Sarcoma in HIV infected patients. Cancers (Basel), 2022, 14(8): 1915.
48.	朱雄杰, 田瑤, 朱娟娟, 等. 食管癌的靶向治療研究進展. 實用醫學雜志, 2017, 33(12): 1910-1912.Zhu XJ, Tian Y, Zhu JJ, et al. Research progress of targeted therapy for esophageal cancer. J Pract Med, 2017, 33(12): 1910-1912.
49.	Moelans CB, van Diest PJ, Milne AN, et al. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int, 2010, 2011: 674182.
50.	Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. Clin Cancer Res, 2018, 24(24): 6248-6256.
51.	Ajani JA, D'Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers, version 1. 2015. J Natl Compr Canc Netw, 2015, 13(2): 194-227.
52.	朱孔彩, 劉煒, 陳喆. 3例HIV感染的消化系統腫瘤患者應用卡瑞利珠單抗的病例分析. 中國藥物應用與監測, 2022, 19(4): 271-274.Zhu KC, Liu W, Chen Z. Case analysis of three HIV patients with gastrointestinal tumors treated by camrelizumab. Chin J Drug Appl Monit, 2022, 19(4): 271-274.
53.	林曜, 張鵬, 陶凱雄. 肛管鱗癌診治研究進展. 中華結直腸疾病電子雜志, 2020, 9(5): 433-439.Lin Y, Zhang P, Tao KX. Progress in diagnosis and treatment of squamous cell anal carcinoma. Chin J Colorec Dis (Electron Ed), 2020, 9(5): 433-439.
54.	李瑞陽, 方琳. 食管癌免疫治療研究進展. 實用腫瘤學雜志, 2021, 35(1): 41-45.Li RY, Fang L. Research progress on immunotherapy of esophageal cancer. Prac Oncol J, 2021, 35(1): 41-45.
55.	Chen K, Wang X, Yang L, et al. The anti-PD-1/PD-L1 immunotherapy for gastric esophageal cancer: A systematic review and meta-analysis and literature review. Cancer Control, 2021, 28: 1073274821997430.
56.	Scilla KA, Zandberg DP, Bentzen SM, et al. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection. Lung Cancer, 2018, 123: 87-90.
57.	Guihot A, Marcelin AG, Massiani MA, et al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann Oncol, 2018, 29(2): 517-518.

1. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS, 2017, 12(1): 6-11.
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
3. 劉宇英, 魏君麗, 江柔, 等. 食管癌的流行病學及篩查研究進展. 中華疾病控制雜志, 2022, 26(7): 839-844.Liu YY, Wei JL, Jiang R, et al. Research progress on the epidemiology and screening of esophageal cancer. Chin J Dis Control Prev, 2022, 26(7): 839-844.
4. Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 2018, 6(5): e555-e567.
5. Kayamba V, Bateman AC, Asombang AW, et al. HIV infection and domestic smoke exposure, but not human papillomavirus, are risk factors for esophageal squamous cell carcinoma in Zambia: A case-control study. Cancer Med, 2015, 4(4): 588-595.
6. Tanaka LF, Latorre MDRDO, Gutierrez EB, et al. Cancer survival in people with AIDS: A population-based study from S?o Paulo, Brazil. Int J Cancer, 2018, 142(3): 524-533.
7. 雷海科, 李小升, 李杰平, 等. 艾滋病合并惡性腫瘤患者臨床特點及預后影響因素. 腫瘤防治研究, 2022, 49(5): 412-417.Lei HK, Li XS, Li JP, et al. Clinical characteristics and prognostic influence factors of patients with AIDS-related malignant tumor. Cancer Res Prev Treat, 2022, 49(5): 412-417.
8. 雷海科, 李小升, 趙玉蘭, 等. 2011―2018年重慶多中心惡性腫瘤出院患者生存分析. 中國腫瘤, 2020, 29(3): 192-198.Lei HK, Li XS, Zhao YL, et al. Survival of discharged malignant tumor patients from multi-centers in Chongqing from 2011 to 2018. China Cancer, 2020, 29(3): 192-198.
9. 胡俊華, 胡艷秋, 許紅霞, 等. 佳木斯市艾滋病抗病毒治療患者生存率及影響因素分析. 中國現代醫生, 2021, 59(19): 10-13.Hu JH, Hu YQ, Xu HX, et al. Analysis of survival rate and influencing factors of AIDS patients treated with antiviral therapy in Jiamusi City. China Mod Doct, 2021, 59(19): 10-13.
10. 鄭武, 趙丁源, 張薇, 等. 湖北省2008—2018年艾滋病抗病毒治療患者生存及影響因素分析. 中國熱帶醫學, 2020, 20(5): 417-422.Zheng W, Zhao DY, Zhang W, et al. Survival time and influence factors of HAART in Hubei, 2008- 2018. China Trop Med, 2020, 20(5): 417-422.
11. 中華醫學會感染病學分會艾滋病丙型肝炎學組, 中國疾病預防控制中心. 中國艾滋病診療指南 (2021年版). 協和醫學雜志, 2022, 13(2): 203-226.Acquired Immunodeficiency Syndrome and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection /acquired immunodeficiency syndrome (2021 edition). Med J Peking Union Med Coll Hosp, 2022, 13(2): 203-226.
12. Mremi A, Mswima J, Mlay MG, et al. Cancer spectrum in HIV-infected patients: A zonal hospital experience in Tanzania. Cancer Treat Res Commun, 2020, 25: 100213.
13. Gheorghi?? V, Conea IF, Radu AMC, et al. Epidemiological trends and therapeutic challenges of malignancies in adult HIV-1-infected patients receiving combination antiretroviral therapy in a tertiary hospital from Romania: An observational retrospective study. J Infect Public Health, 2019, 12(2): 182-189.
14. 黃曦悅, 石明巧, 茍瑜, 等. 64例HIV/AIDS患者合并腫瘤臨床特征分析. 四川醫學, 2018, 39(7): 743-747.Huang XY, Shi MQ, Gou Y, et al. Analysis of the clinical features of 64 cases of HIV/AIDS patients with tumor. Sichuan Med J, 2018, 39(7): 743-747.
15. 張珂, 熊英, 吳立春, 等. 腫瘤患者中HIV感染狀況的初步調查分析. 腫瘤預防與治療, 2011, 24(2): 83-85.Zhang K, Xiong Y, Wu LC, et al. Investigation of HIV infection status in cancer patients. Cancer Res Prev Treat, 2011, 24(2): 83-85.
16. 陳瓊, 徐慧芳, 劉曙正, 等. 2010—2016年河南省食管癌發病與死亡情況趨勢分析. 中華腫瘤雜志, 2022, 44(1): 86-92.Chen Q, Xu HF, Liu SZ, et al. Changing trend of incidence and mortality of esophageal cancer during 2010-2016 in Henan Province, China. Chin J Oncol, 2022, 44(1): 86-92.
17. Alongi F, Giaj-Levra N, Sciascia S, et al. Radiotherapy in patients with HIV: Current issues and review of the literature. Lancet Oncol, 2017, 18(7): e379-e393.
18. Thrift AP, Kramer JR, Hartman CM, et al. Risk and predictors of esophageal and stomach cancers in HIV-infected veterans: A matched cohort study. J Acquir Immune Defic Syndr, 2019, 81(3): e65-e72.
19. Holleczek B, Sch?ttker B, Brenner H. Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: Results from the prospective population-based ESTHER cohort study. Int J Cancer, 2020, 146(10): 2773-2783.
20. Fialho AB, Braga-Neto MB, Guerra EJ, et al. Low prevalence of H. pylori infection in HIV-positive patients in the northeast of Brazil. BMC Gastroenterol, 2011, 11: 13.
21. Hestvik E, Tylleskar T, Ndeezi G, et al. Prevalence of Helicobacter pylori in HIV-infected, HAART-na?ve Ugandan children: A hospital-based survey. J Int AIDS Soc, 2011, 14: 34.
22. Vohlonen IJ, Hakama M, H?rk?nen M, et al. Oesophageal cancer incidence in 20-year follow-up in a population-based sample of 12 000 middle-age men with or without Helicobacter pylori infection in Finland. Gut, 2018, 67(6): 1201-1202.
23. Wilcox CM. Esophageal disease in the acquired immunodeficiency syndrome: Etiology, diagnosis, and management. Am J Med, 1992, 92(4): 412-421.
24. Guaitoli G, Baldessari C, Maur M, et al. Treating cancer with immunotherapy in HIV-positive patients: A challenging reality. Crit Rev Oncol Hematol, 2020, 145: 102836.
25. 張永喜, 桂希恩, 鐘亞華, 等. 艾滋病病毒感染人群中惡性腫瘤的常見類型及其生存分析. 腫瘤研究與臨床, 2010, 22(11): 764-766.Zhang YX, Gui XE, Zhong YH, et al. Spectrum and survival of cancer in cohort of HIV-infected population. Cancer Res Clin, 2010, 22(11): 764-766.
26. Torres HA, Mulanovich V. Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis, 2014, 59(1): 106-114.
27. 霍小東, 于振濤. 多學科團隊在食管癌診斷與治療中的作用. 中國腫瘤臨床, 2016, 43(12): 502-506.Huo XD, Yu ZT. The role of a multidisciplinary team in diagnosing and treating esophageal cancer. Chin J Clin Oncol, 2016, 43(12): 502-506.
28. Mwachiro M, Mitchell E, Topazian HM, et al. Esophagectomy in patients with human immunodeficiency virus and acquired immune deficiency syndrome: A viable option. Semin Thorac Cardiovasc Surg, 2018, 30(1): 116-121.
29. Davakis S, Syllaios A, Meropouli A, et al. Minimally invasive oesophagectomy for cancer in patients with HIV/AIDS: Considerations and future directions. Ann R Coll Surg Engl, 2020, 102(9): e1-e3.
30. 中國性病艾滋病防治協會學術委員會外科學組, 中華醫學會熱帶病與寄生蟲學分會外科學組, 國家傳染病醫學中心(北京). 中國人類免疫缺陷病毒感染者圍手術期抗病毒治療專家共識 (第二版). 中華實驗和臨床感染病雜志(電子版), 2021, 15(5): 289-294.Surgical Group of Chinese Association of STD and AIDS Prevention and Control, Surgical Group of Tropical Disease and Parasitology Branch of Chinese Medical Association, National Medical Center for Infectious Diseases (Beijing). Expert consensus on perioperative antiviral therapy for human immunodeficiency virus infected population in China (Second edition). Chin J Exp Clin Infect Dis (Electron Ed), 2021, 15(5): 289-294.
31. Guild GN, Moore TJ, Barnes W, et al. CD4 count is associated with postoperative infection in patients with orthopaedic trauma who are HIV positive. Clin Orthop Relat Res, 2012, 470(5): 1507-1512.
32. Li J, Li H, Zeng H, et al. A study protocol of population-based cancer screening cohort study on esophageal, stomach and liver cancer in rural China. Chin J Cancer Res, 2020, 32(4): 540-546.
33. 王付亮. 食管癌新輔助化療. 河北醫科大學, 2018.Wang FL. Neo-adjuvant chemotherapy for esophageal cancer. Hebei Medical University, 2018.
34. Yano T, Kasai H, Horimatsu T, et al. A multicenter phaseⅡstudy of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Oncotarget, 2017, 8(13): 22135-22144.
35. Kelly RJ. Immunotherapy for esophageal and gastric cancer. Am Soc Clin Oncol Educ Book, 2017, 37: 292-300.
36. 路遙, 孟祥瑞, 許孟麗, 等. PD-1/PD-L1抑制劑在食管癌臨床研究進展. 食管疾病, 2020, 2(3): 222-227.Lu Y, Meng XR, Xu ML, et al. Clinical research progress of PD-1/PD-L1 inhibitors in esophageal cancer. J Esophag Dis, 2020, 2(3): 222-227.
37. Phakathi BP, Basson G, Karusseit VOL, et al. The effect of HIV infection on the surgical, chemo- and radiotherapy management of breast cancer. A prospective cohort study. Int J Surg, 2016, 34: 109-115.
38. Issa RA, Podbielski FJ, Fontaine JP, et al. Esophagectomy in a patient with AIDS. Dis Esophagus, 2004, 17(3): 270-272.
39. 夏咸軍, 劉保池. 艾滋病與惡性腫瘤. 上海醫藥, 2013, 34(16): 11-14.Xia XJ, Liu BC. AIDS and cancer. Shanghai Med Pharm J, 2013, 34(16): 11-14.
40. 國家衛生健康委員會. 食管癌診療規范(2018年版). 中華消化病與影像雜志(電子版), 2019, 9(4): 158-192.National Health Commission. Esophageal cancer diagnostic and treatment guidelines (2018 edition). Chin J Digest Med Imageol (Electron Ed), 2019, 9(4): 158-192.
41. Formenti SC, Chak L, Gill P, et al. Increased radiosensitivity of normal tissue fibroblasts in patients with acquired immunodeficiency syndrome (AIDS) and with Kaposi's sarcoma. Int J Radiat Biol, 1995, 68(4): 411-412.
42. Wijsman JA, Dekaban GA, Rieder MJ. Differential toxicity of reactive metabolites of clindamycin and sulfonamides in HIV-infected cells: Influence of HIV infection on clindamycin toxicity in vitro. J Clin Pharmacol, 2005, 45(3): 346-351.
43. Pajonk F, Himmelsbach J, Riess K, et al. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res, 2002, 62(18): 5230-5235.
44. Wolchok JD, Chan TA. Cancer: Antitumour immunity gets a boost. Nature, 2014, 515(7528): 496-498.
45. Vanpouille-Box C, Pilones KA, Wennerberg E, et al. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine, 2015, 33(51): 7415-7422.
46. 丁祥, 于淑慧, 龍清, 等. 人類免疫缺陷病毒陽性惡性腫瘤患者放射治療的急性放射性反應觀察. 中華放射醫學與防護雜志, 2015, 35(9): 687-689.Ding X, Yu SH, Long Q, et al. Acute adverse effects of radiotherapy on HIV-positive patients with malignancy. Chin J Radiol Med Prot, 2015, 35(9): 687-689.
47. Quéro L, Palich R, Valantin MA, et al. The role of radiotherapy in treating Kaposi's Sarcoma in HIV infected patients. Cancers (Basel), 2022, 14(8): 1915.
48. 朱雄杰, 田瑤, 朱娟娟, 等. 食管癌的靶向治療研究進展. 實用醫學雜志, 2017, 33(12): 1910-1912.Zhu XJ, Tian Y, Zhu JJ, et al. Research progress of targeted therapy for esophageal cancer. J Pract Med, 2017, 33(12): 1910-1912.
49. Moelans CB, van Diest PJ, Milne AN, et al. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int, 2010, 2011: 674182.
50. Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. Clin Cancer Res, 2018, 24(24): 6248-6256.
51. Ajani JA, D'Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers, version 1. 2015. J Natl Compr Canc Netw, 2015, 13(2): 194-227.
52. 朱孔彩, 劉煒, 陳喆. 3例HIV感染的消化系統腫瘤患者應用卡瑞利珠單抗的病例分析. 中國藥物應用與監測, 2022, 19(4): 271-274.Zhu KC, Liu W, Chen Z. Case analysis of three HIV patients with gastrointestinal tumors treated by camrelizumab. Chin J Drug Appl Monit, 2022, 19(4): 271-274.
53. 林曜, 張鵬, 陶凱雄. 肛管鱗癌診治研究進展. 中華結直腸疾病電子雜志, 2020, 9(5): 433-439.Lin Y, Zhang P, Tao KX. Progress in diagnosis and treatment of squamous cell anal carcinoma. Chin J Colorec Dis (Electron Ed), 2020, 9(5): 433-439.
54. 李瑞陽, 方琳. 食管癌免疫治療研究進展. 實用腫瘤學雜志, 2021, 35(1): 41-45.Li RY, Fang L. Research progress on immunotherapy of esophageal cancer. Prac Oncol J, 2021, 35(1): 41-45.
55. Chen K, Wang X, Yang L, et al. The anti-PD-1/PD-L1 immunotherapy for gastric esophageal cancer: A systematic review and meta-analysis and literature review. Cancer Control, 2021, 28: 1073274821997430.
56. Scilla KA, Zandberg DP, Bentzen SM, et al. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection. Lung Cancer, 2018, 123: 87-90.
57. Guihot A, Marcelin AG, Massiani MA, et al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann Oncol, 2018, 29(2): 517-518.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Epidemiological characteristics and progress in diagnosis and treatment of esophageal cancer with human immunodeficiency virus/acquired immune deficiency syndrome

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content